Compare Stocks: BPTH, VINC, SISI, and CARM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPTH Bio-Path	$0.00 -60.0%	$0.03	$0.00 ▼ $0.11	$11K	-0.53	29,684 shs	16,009 shs
CARM Carisma Therapeutics	$0.00 -36.4%	$0.00	$0.00 ▼ $0.30	$29K	-9.02	59,439 shs	1,300 shs
SISI Shineco	$0.11	$0.01	$0.00 ▼ $6.79	$44K	-1.76	1,989 shs	80 shs
VINC Vincerx Pharma	$0.02	$0.01	$0.00 ▼ $0.07	$79K	1.41	4,799 shs	250 shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPTH Bio-Path	0.00%	+400.00%	-98.49%	-98.82%	-99.16%
CARM Carisma Therapeutics	-36.36%	-12.50%	-69.57%	-91.36%	-99.75%
SISI Shineco	0.00%	+52,400.00%	+34,900.00%	+4,900.00%	-98.37%
VINC Vincerx Pharma	0.00%	0.00%	+18.11%	+18.11%	-60.84%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPTH Bio-Path	$0.00 -60.0%	$0.03	$0.00 ▼ $0.11	$11K	-0.53	29,684 shs	16,009 shs
CARM Carisma Therapeutics	$0.00 -36.4%	$0.00	$0.00 ▼ $0.30	$29K	-9.02	59,439 shs	1,300 shs
SISI Shineco	$0.11	$0.01	$0.00 ▼ $6.79	$44K	-1.76	1,989 shs	80 shs
VINC Vincerx Pharma	$0.02	$0.01	$0.00 ▼ $0.07	$79K	1.41	4,799 shs	250 shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPTH Bio-Path	0.00%	+400.00%	-98.49%	-98.82%	-99.16%
CARM Carisma Therapeutics	-36.36%	-12.50%	-69.57%	-91.36%	-99.75%
SISI Shineco	0.00%	+52,400.00%	+34,900.00%	+4,900.00%	-98.37%
VINC Vincerx Pharma	0.00%	0.00%	+18.11%	+18.11%	-60.84%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BPTH Bio-Path	0.00	N/A	N/A	N/A
CARM Carisma Therapeutics	1.00	Sell	N/A	N/A
SISI Shineco	1.00	Sell	N/A	N/A
VINC Vincerx Pharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BPTH Bio-Path	N/A	N/A	N/A	N/A	$0.71 per share	N/A
CARM Carisma Therapeutics	$10.77M	0.00	N/A	N/A	($0.67) per share	0.00
SISI Shineco	$9.60M	0.00	N/A	N/A	$4,679.15 per share	0.00
VINC Vincerx Pharma	N/A	N/A	N/A	N/A	$10.50 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BPTH Bio-Path	-$16.08M	-$1.09	N/A	N/A	N/A	N/A	-2,842.40%	-337.48%	11/12/2026 (Estimated)
CARM Carisma Therapeutics	-$60.48M	$0.73	0.00	N/A	N/A	-254.28%	N/A	-192.17%	11/5/2026 (Estimated)
SISI Shineco	-$22.45M	-$204.00	N/A	N/A	N/A	-380.55%	-79.89%	-33.01%	N/A
VINC Vincerx Pharma	-$40.16M	-$5.31	N/A	N/A	N/A	N/A	-248.33%	-132.73%	11/10/2026 (Estimated)

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BPTH Bio-Path	N/A	N/A	N/A	N/A	N/A
CARM Carisma Therapeutics	N/A	N/A	N/A	N/A	N/A
SISI Shineco	N/A	N/A	N/A	N/A	N/A
VINC Vincerx Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BPTH Bio-Path	N/A	0.86	0.86
CARM Carisma Therapeutics	N/A	0.48	0.48
SISI Shineco	N/A	0.72	0.71
VINC Vincerx Pharma	N/A	2.17	2.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BPTH Bio-Path	5.74%
CARM Carisma Therapeutics	44.27%
SISI Shineco	4.08%
VINC Vincerx Pharma	44.02%

Insider Ownership

Company	Insider Ownership
BPTH Bio-Path	0.72%
CARM Carisma Therapeutics	6.90%
SISI Shineco	0.02%
VINC Vincerx Pharma	15.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BPTH Bio-Path	10	53.90 million	5.73 million	No Data
CARM Carisma Therapeutics	20	41.85 million	38.91 million	No Data
SISI Shineco	119	415,000	415,000	Not Optionable
VINC Vincerx Pharma	60	5.23 million	1.89 million	Not Optionable

BPTH, VINC, SISI, and CARM Headlines

Recent News About These Companies

Antibody Drug Conjugates (ADC) Market Research and Competitive Landscape Report 2026 - Extensive Analysis of Over 180 Companies and More Than 290 Drugs

April 14, 2026 | finance.yahoo.com

Contrasting Vincerx Pharma (NASDAQ:VINC) and iBio (NYSE:IBIO)

January 18, 2026 | defenseworld.netD

Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders ...

July 16, 2025 | gurufocus.com

Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution Proposal

July 16, 2025 | globenewswire.com

Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders | The ... - The Manila Times

July 9, 2025 | manilatimes.netM

Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders - Morningstar

July 9, 2025 | morningstar.comM

Vincerx Pharma, Inc. Common Stock (VINC) - Yahoo Finance

July 8, 2025 | finance.yahoo.com

Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders

July 7, 2025 | globenewswire.com

Vincerx Pharma, Inc. (VINC) - Yahoo Finance

July 2, 2025 | ca.finance.yahoo.com

Vincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal

June 18, 2025 | globenewswire.com

Vincerx Pharma announces plan to delist from Nasdaq

April 18, 2025 | markets.businessinsider.com

Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC

April 17, 2025 | finance.yahoo.com

Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC

April 17, 2025 | globenewswire.com

Vincerx's final merger attempt collapses, leaving ADC biotech to wind down

April 9, 2025 | fiercebiotech.comF

Vincerx terminates letter of intent with Global Digital, initiates wind down

April 9, 2025 | markets.businessinsider.com

Financially struggling drugmaker's potential rescue falls apart. It now will wind down

April 9, 2025 | bizjournals.com

Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities

April 8, 2025 | globenewswire.com

Vincerx Pharma announces non-binding LOI for Qumulus AI combination

March 18, 2025 | markets.businessinsider.com

Vincerx Pharma, Inc.: Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI

March 18, 2025 | finanznachrichten.de

Vincerx, left in limbo by collapsed deal, moves to merge with AI company to escape cash crisis

March 18, 2025 | fiercebiotech.comF

New MarketBeat Followers Over Time

BPTH, VINC, SISI, and CARM Company Descriptions

Bio-Path NASDAQ:BPTH

$0.0002 0.00 (-60.00%)

As of 10:57 AM Eastern

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

Carisma Therapeutics NASDAQ:CARM

$0.0007 0.00 (-36.36%)

As of 12:31 PM Eastern

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Shineco NASDAQ:SISI

$0.10 0.00 (0.00%)

As of 09/23/2026

Shineco, Inc., through its subsidiaries, processes and distributes agricultural produce. It also engages in the growing and cultivation of mulberry trees and silkworm cocoons; distribution of fruit business; and processing and distribution of silk and silk fabrics, as well as other by-products. The company was incorporated in 1997 and is headquartered in Beijing, the People's Republic of China.

Vincerx Pharma NASDAQ:VINC

$0.02 0.00 (0.00%)

As of 09/23/2026 09:30 AM Eastern

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Compare Profitability & Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BPTH, VINC, SISI, and CARM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

BPTH, VINC, SISI, and CARM Company Descriptions

Bio-Path NASDAQ:BPTH

Carisma Therapeutics NASDAQ:CARM

Shineco NASDAQ:SISI

Vincerx Pharma NASDAQ:VINC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Compare Profitability & Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BPTH, VINC, SISI, and CARM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

BPTH, VINC, SISI, and CARM Company Descriptions

Bio-Path NASDAQ:BPTH

Carisma Therapeutics NASDAQ:CARM

Shineco NASDAQ:SISI

Vincerx Pharma NASDAQ:VINC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools